Because levetiracetam has a prominent effect on epilepsy and neuroinflammation-associated brain circuit reorganization, we first compared its effect with brivaracetam, a novel and more potent SV2A ligand, on glial and neuronal cell density changes by investigating brain regions that are especially vulnerable to kainic acid and could contribute to abnormal function of epileptic circuits. Here, SV2A is linked to epilepsy.